Oxford Immunotec Global PLC (OXFD) Expected to Announce Quarterly Sales of $33.58 Million
Equities research analysts expect Oxford Immunotec Global PLC (NASDAQ:OXFD) to post sales of $33.58 million for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Oxford Immunotec Global’s earnings. The highest sales estimate is $33.74 million and the lowest is $33.39 million. Oxford Immunotec Global posted sales of $30.43 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 10.4%. The firm is scheduled to announce its next earnings report on Tuesday, October 30th.
On average, analysts expect that Oxford Immunotec Global will report full year sales of $113.16 million for the current year, with estimates ranging from $112.82 million to $113.60 million. For the next financial year, analysts anticipate that the business will report sales of $127.61 million per share, with estimates ranging from $125.28 million to $129.54 million. Zacks Investment Research’s sales averages are an average based on a survey of research firms that cover Oxford Immunotec Global.
Oxford Immunotec Global (NASDAQ:OXFD) last announced its earnings results on Tuesday, July 31st. The company reported ($0.25) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.25). Oxford Immunotec Global had a negative net margin of 23.41% and a negative return on equity of 39.85%. The business had revenue of $29.32 million for the quarter, compared to analyst estimates of $28.58 million. During the same quarter last year, the business earned ($0.74) earnings per share. The company’s revenue for the quarter was up 12.3% compared to the same quarter last year.
Shares of NASDAQ OXFD traded up $0.28 during trading on Monday, hitting $15.03. The company had a trading volume of 238,403 shares, compared to its average volume of 65,479. Oxford Immunotec Global has a fifty-two week low of $10.00 and a fifty-two week high of $17.41. The firm has a market cap of $383.02 million, a price-to-earnings ratio of -11.05 and a beta of -0.20. The company has a quick ratio of 4.86, a current ratio of 5.39 and a debt-to-equity ratio of 0.41.
In related news, Director Richard A. Sandberg sold 3,000 shares of the business’s stock in a transaction dated Wednesday, August 1st. The shares were sold at an average price of $13.15, for a total transaction of $39,450.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 6.61% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Redmile Group LLC boosted its position in Oxford Immunotec Global by 6.5% during the first quarter. Redmile Group LLC now owns 2,469,687 shares of the company’s stock worth $30,748,000 after acquiring an additional 151,300 shares during the last quarter. BlackRock Inc. boosted its holdings in Oxford Immunotec Global by 10.0% in the 2nd quarter. BlackRock Inc. now owns 1,279,324 shares of the company’s stock valued at $16,490,000 after purchasing an additional 116,814 shares during the last quarter. First Light Asset Management LLC boosted its holdings in Oxford Immunotec Global by 98.0% in the 2nd quarter. First Light Asset Management LLC now owns 1,240,391 shares of the company’s stock valued at $15,989,000 after purchasing an additional 613,806 shares during the last quarter. Wasatch Advisors Inc. boosted its holdings in Oxford Immunotec Global by 18.6% in the 2nd quarter. Wasatch Advisors Inc. now owns 883,761 shares of the company’s stock valued at $11,392,000 after purchasing an additional 138,571 shares during the last quarter. Finally, Granahan Investment Management Inc. MA boosted its holdings in Oxford Immunotec Global by 9.1% in the 2nd quarter. Granahan Investment Management Inc. MA now owns 565,332 shares of the company’s stock valued at $7,287,000 after purchasing an additional 47,159 shares during the last quarter. Hedge funds and other institutional investors own 91.78% of the company’s stock.
Oxford Immunotec Global Company Profile
Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for underserved immune-regulated conditions. Its development activities principally focus on the areas of infectious diseases, transplantation, autoimmune and inflammatory disease, and immune-oncology.
Recommended Story: Asset Allocation
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.